Coleman Gross

TL;DR: Mifepristone produced significant clinical and metabolic improvement in patients with CS with an acceptable risk-benefit profile during 6 months of treatment, and had significant improvement in clinical status.

TL;DR: In the largest prospective study to date, long-term mifepristone treatment increased ACTH in approximately two-thirds of patients with Cushing's disease patients and generally remained stable over time.

TL;DR: Clinical trial data have shown that mifepristone improves glycemic control and blood pressure, causes weight loss and a decrease in waist circumference, lessens depression, and improves overall wellbeing, however, adverse effects include adrenal insufficiency, hypokalemia, and endometrial thickening with vaginal bleeding.

TL;DR: Treatment with mifepristone reduced HDL-C, HDL particle concentration, and serum HDL cholesterol efflux in postmenopausal women, however, on a per particle basis, the efflux capacity of serum HDL increased and support the concept that a decrease in HDL- C may not represent proportional impairment of HDL function.

TL;DR: Using oral glucose tolerance test data from SEISMIC, whole-body insulin sensitivity, β-cell function, insulinogenic index, homeostasis model assessment-β [HOMA-β], disposition index, weight, and waist circumference over time were assessed.